MaxCyte, Inc. (MXCT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 26 | 34 | 44 | 41 | 39 | 33 | 31 | 31 |
| Operating profit | $m | -45 | -35 | ||||||
| Net profit | $m | -12 | -19 | -24 | -38 | -41 | -45 | -36 | -30 |
| EPS reported | $ | -0.42 | -0.33 | ||||||
| Operating cashflow per share | $ | -0.32 | -0.22 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -0.34 | -0.22 | ||||||
| Free cash flow | $m | -36 | -24 | ||||||
| Net debt | $m | -102 | -106 | ||||||
| Book value equity | $m | 171 | 159 | ||||||
| Book value per share | $ | 1.61 | 1.49 | ||||||
| Number of shares | m | 106.43 | 106.82 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.96 | 1.04 | ||||||
| P/S LTM | x | 4.99 | 5.31 | ||||||
| P/FCF LTM | x | -4.56 | -6.93 | ||||||
| EV/EBITDA LTM | x | -4.12 | -5.02 | ||||||
| EV/Sales LTM | x | 4.93 | 4.62 | ||||||
| Earnings Yield LTM | % | -27.05% | -25.27% | ||||||
| FCF Yield | % | -21.93% | -14.42% | ||||||
| Quality | |||||||||
| ROE | % | -26.02% | -21.01% | ||||||
| ROIC | % | -23.87% | -19.66% | ||||||
| Operating margin | % | -1.37% | -1.12% | ||||||
| Gross margin | % | +81.16% | +79.43% | ||||||
| FCF/Sales | % | -109.54% | -76.62% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -14.50% | -19.61% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.02 | -1.38 | ||||||
| Net Debt/EBITDA | x | 0.05 | -0.07 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.88% | 0.00% | ||||||
| Net debt/Equity | x | -0.59 | -0.67 | ||||||
| Gross debt/equity | x | 0.10 | 0.11 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free